Form 8-A12B INNOCAN PHARMA Corp

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF

THE SECURITIES EXCHANGE ACT OF l934

 

INNOCAN PHARMA CORPORATION

(Exact name of Registrant as specified in its charter)

 

Canada		Not Applicable
(State of incorporation or organization)		(I.R.S. Employer Identification No.)

 

1015, 926 – 5 Avenue SW Calgary, Alberta, Canada +1 (516) 210-4025		T2P 0N7
(Address of principal executive offices)		(Zip Code)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class to be so registered		Name of each exchange on which each class is to be registered
Common Shares, no par value		The Nasdaq Stock Market LLC

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box. ☒

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), please check the following box. ☐

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

 

Securities Act registration statement file number to which this form relates:

333-288899

 

Securities to be registered pursuant to Section 12(g) of the Act:

None

(Title of Class)

 

 

 

Item 1. Description of Registrant’s Securities to be Registered.

 

Innocan Pharma Corporation (the “Registrant”) hereby incorporates by reference the description of its common shares, no par value, to be registered hereunder, contained under the heading “Description of Share Capital” in the Company’s Registration Statement on Form F-1 (File No. 333-288899), originally filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”) on July 23, 2025, as subsequently amended (the “Registration Statement”), and any prospectus that constitutes part of the Registration Statement and that is subsequently filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, which information shall be deemed to be incorporated herein by reference.

 

Item 2. Exhibits.

 

Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed because no other securities of the Company are registered on The Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Innocan Pharma Corporation
	By:	/s/ Iris Bincovich
	Name:	Iris Bincovich
	Title:	Chief Executive Officer

 

Dated: September 22, 2025

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• GSI Disability Insurance Window Opens to First Medical Resident Class Without Grad PLUS Loan Protection
• Strathmore Announces Drilling Plans for Beaver Rim in the Prolific Gas Hills District
• LitVM Testnet Surpasses 4.4 Million Wallets and 63 Million Transactions as AI-Powered DeFi Ecosystem Takes Shape on Litecoin